HUE064449T2 - Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra - Google Patents

Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra

Info

Publication number
HUE064449T2
HUE064449T2 HUE15818148A HUE15818148A HUE064449T2 HU E064449 T2 HUE064449 T2 HU E064449T2 HU E15818148 A HUE15818148 A HU E15818148A HU E15818148 A HUE15818148 A HU E15818148A HU E064449 T2 HUE064449 T2 HU E064449T2
Authority
HU
Hungary
Prior art keywords
hepatitis
phosphorotiotated
chelated
treatment
nucleic acid
Prior art date
Application number
HUE15818148A
Other languages
English (en)
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE064449(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of HUE064449T2 publication Critical patent/HUE064449T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HUE15818148A 2014-07-10 2015-07-07 Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra HUE064449T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15

Publications (1)

Publication Number Publication Date
HUE064449T2 true HUE064449T2 (hu) 2024-03-28

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15818148A HUE064449T2 (hu) 2014-07-10 2015-07-07 Kelátozott foszfortioált nukleinsav polimerek egy HBV polimeráz inhibitorral kombinációban hepatitis B és hepatitis D kezelésére történõ alkalmazásra

Country Status (32)

Country Link
US (1) US9603865B2 (hu)
EP (1) EP3166615B1 (hu)
JP (2) JP2017521433A (hu)
KR (2) KR20230070330A (hu)
CN (2) CN106659730A (hu)
AU (1) AU2015286199B2 (hu)
BR (1) BR112017000320B1 (hu)
CA (1) CA2954182C (hu)
CL (1) CL2017000008A1 (hu)
CU (1) CU20170001A7 (hu)
DK (1) DK3166615T3 (hu)
DO (1) DOP2017000002A (hu)
EA (1) EA036745B1 (hu)
EC (1) ECSP16097355A (hu)
ES (1) ES2963814T3 (hu)
FI (1) FI3166615T3 (hu)
HK (1) HK1231402A1 (hu)
HR (1) HRP20231400T1 (hu)
HU (1) HUE064449T2 (hu)
IL (1) IL249660B (hu)
LT (1) LT3166615T (hu)
MD (1) MD4760C8 (hu)
MX (1) MX2017000053A (hu)
MY (1) MY178087A (hu)
PH (1) PH12017500010A1 (hu)
PL (1) PL3166615T3 (hu)
PT (1) PT3166615T (hu)
RS (1) RS64833B1 (hu)
SG (1) SG11201700073PA (hu)
SI (1) SI3166615T1 (hu)
TW (1) TWI766831B (hu)
WO (1) WO2016004525A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
KR20210090217A (ko) * 2018-11-08 2021-07-19 알리고스 테라퓨틱스 인코포레이티드 S-항원 수송 저해 올리고뉴클레오타이드 중합체 및 방법
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113651852A (zh) * 2020-05-07 2021-11-16 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦e晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816A (zh) * 2020-07-30 2022-02-18 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
EA026660B1 (ru) 2010-08-20 2017-05-31 Репликор Инк. Введение олигонуклеотидов в виде хелатных комплексов
WO2012058210A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
MX346239B (es) 2012-05-18 2017-03-13 Replicor Inc Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido.
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
SI3166615T1 (sl) 2023-12-29
JP6922030B2 (ja) 2021-08-18
ECSP16097355A (es) 2017-03-31
US20160008393A1 (en) 2016-01-14
JP2020143065A (ja) 2020-09-10
HK1231402A1 (zh) 2017-12-22
PT3166615T (pt) 2023-11-13
AU2015286199A1 (en) 2017-02-23
MD4760C8 (ro) 2022-02-28
DK3166615T3 (da) 2023-11-13
IL249660A0 (en) 2017-02-28
US9603865B2 (en) 2017-03-28
BR112017000320A2 (pt) 2017-11-07
LT3166615T (lt) 2024-01-25
TW201613617A (en) 2016-04-16
EP3166615A1 (en) 2017-05-17
MX2017000053A (es) 2017-05-01
JP2017521433A (ja) 2017-08-03
CN106659730A (zh) 2017-05-10
EA201790160A1 (ru) 2017-06-30
DOP2017000002A (es) 2017-03-15
EP3166615A4 (en) 2018-01-17
AU2015286199B2 (en) 2020-05-14
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
TWI766831B (zh) 2022-06-11
CN113750112A (zh) 2021-12-07
PH12017500010A1 (en) 2017-05-15
CA2954182A1 (en) 2016-01-14
PL3166615T3 (pl) 2024-02-19
KR20170029577A (ko) 2017-03-15
EA036745B1 (ru) 2020-12-16
BR112017000320B1 (pt) 2023-02-07
CL2017000008A1 (es) 2017-06-09
MD20170014A2 (ro) 2017-07-31
KR20230070330A (ko) 2023-05-22
CA2954182C (en) 2023-08-15
MY178087A (en) 2020-10-02
EP3166615B1 (en) 2023-08-09
WO2016004525A1 (en) 2016-01-14
SG11201700073PA (en) 2017-02-27
ES2963814T3 (es) 2024-04-02
RS64833B1 (sr) 2023-12-29
MD4760B1 (ro) 2021-07-31
FI3166615T3 (fi) 2023-11-06
HRP20231400T1 (hr) 2024-02-16

Similar Documents

Publication Publication Date Title
LT3166615T (lt) Chelatiniai fosforotioato nukleorūgšties polimerai, skirti panaudoti derinyje su hbv polimerazės inhibitoriumi hepatito b ir hepatito d virusinių infekcijų gydymui
HK1248681A1 (zh) 作為hbsag(hbv表面抗原)和hbv dna生成的抑制劑用於治療乙型肝炎病毒感染的四氫吡啶並嘧啶和四氫吡啶並吡啶類化合物
IL272820B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
IL265921A (en) Transgenic meganonucleases specific for recognition sequences in the hepatitis b virus genome
HK1251010A1 (zh) 用於治療乙型肝炎病毒(hbv)感染的試劑及用途
SI3137078T1 (sl) Zdravljenje okužbe s hepatitis delta virusom
HK1249514A1 (zh) C型肝炎病毒聚合酶的抑制劑
EP3463469C0 (en) COMBINATION OF LEDIPASVIR AND SOFOSBUVIR FOR USE IN THE TREATMENT OF HEPATITIS B IN HUMAN
HK1243712A1 (zh) 作為用於治療丙型肝炎的hcv抑制劑的核苷酸衍生物
IL286484B (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
TH1601002531A (th) กรดนิวคลีอิกและวิธีการสำหรับการตรวจหาเชื้อก่อโรคและจุลินทรีย์ที่เป็นประโยชน์
TH1601001266A (th) วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b
AU2015901617A0 (en) Reagents for treatment of hepatitis B virus (HBV) infection and use thereof